Literature DB >> 7694336

Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice.

T Nakamura1, I Ebihara, M Fukui, S Osada, Y Tomino, T Masaki, K Goto, Y Furuichi, H Koide.   

Abstract

Endothelin (ET)-1, ET-3, and ET receptors are widely distributed in the vascular system and the kidney. The present study was designed to measure the renal concentrations of ET-1, ET-3, and ET receptor mRNAs in NZB/W F1 mice at 8, 24, and 48 weeks of age. The renal concentration of ET-1 mRNA increased significantly in NZB/W F1 mice as their nephritis progressed, reaching, by 48 weeks, a 10-fold higher concentration than in control NZW mice. Renal ET-3 mRNA concentrations, however, remained unchanged. The renal concentrations of ET receptor A and B mRNAs in NZB/W F1 mice increased gradually with the progression of nephritis, reaching 5- and 3-fold higher concentrations, respectively, at 48 weeks of age than found in control mice. Transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) have been shown to stimulate ET-1 mRNA expression in cultured mesangial cells. We therefore also examined the concentrations of TGF-beta and TNF-alpha mRNAs in the renal tissues of NZB/W F1 mice, and found that, at 48 weeks of age, they were 10- and 8-fold higher, respectively, than in control NZW mice. At 24 weeks, NZB/W F1 mice were divided into two groups receiving either methylprednisolone (MPSL) or saline injections for the following 24 weeks. The development of the histologic lesions characteristic of lupus nephritis and the increased renal concentrations of ET-1, ET receptors, TGF-beta and TNF-alpha mRNAs were suppressed by MPSL treatment. These data suggest that ET and ET receptor gene transcription is upregulated in the renal tissues of NZB/W F1 mice and that the beneficial treatment of lupus nephritis with MPSL is accompanied by a reduction in the elevated concentrations of ET-1, ET receptors, TGF-beta and TNF-alpha mRNAs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694336     DOI: 10.1159/000173768

Source DB:  PubMed          Journal:  Ren Physiol Biochem        ISSN: 1011-6524


  11 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 3.  Role of endothelin-1 in acute lung injury.

Authors:  Alejandro P Comellas; Arturo Briva
Journal:  Transl Res       Date:  2009-03-20       Impact factor: 7.012

Review 4.  Anti-TNF-alpha therapies in systemic lupus erythematosus.

Authors:  Lang-Jing Zhu; Xiao Yang; Xue-Qing Yu
Journal:  J Biomed Biotechnol       Date:  2010-06-22

5.  Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.

Authors:  Elena L Dent; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09

6.  Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells.

Authors:  Adisak Suwanichkul; Scott E Wenderfer
Journal:  Mol Immunol       Date:  2013-08-01       Impact factor: 4.407

Review 7.  The pathophysiology of hypertension in systemic lupus erythematosus.

Authors:  Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-21       Impact factor: 3.619

Review 8.  Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Authors:  G Noll; R R Wenzel; T F Lüscher
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 9.  Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.

Authors:  Ariela Benigni; Simona Buelli; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2020-03-17       Impact factor: 3.714

10.  SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus.

Authors:  Martin Aringer; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2003-05-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.